Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2005-01-11 Investor Presentation
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Akquisition Labesfal - Jan 7, 2005
Investor Presentation
2005-01-11 English
Fresenius AG:Fresenius Kabi acquires Labesfal
M&A Activity Classification · 99% confidence The document is an 'Ad hoc announcement' dated January 7, 2005, detailing the acquisition of Labesfal by Fresenius Kabi, a subsidiary of Fresenius AG. This type of announcement, concerning a significant corporate transaction like a merger or takeover bid, directly aligns with the definition of M&A Activity (TAR). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it describes a specific transaction. Filing Type Selected: TAR (M&A Activity).
2005-01-07 English
Analysts´ Meeting November 2, 2004
Investor Presentation Classification · 95% confidence The document is titled 'Analysts' Meeting, November 2, 2004' and contains detailed financial data and business updates for the first nine months of 2004, including sales, EBIT, and outlooks for various business segments. It is structured as a presentation with agenda items such as business updates, financials, and outlook, typical of investor or analyst presentations. The content is focused on financial performance, strategy, and market position rather than a formal annual or quarterly report. There is no indication that this is a full annual report (10-K) or an interim report (IR), nor is it a transcript of a call or a regulatory filing. Given the detailed financial and strategic information presented in a slide format, this document best fits the category of an Investor Presentation (IP).
2004-11-17 English
Q3 Report 2004
Interim / Quarterly Report
2004-11-15 German
Fresenius Group - First nine months 2004
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc-announcement' dated November 2, 2004, detailing the financial performance for the 'First nine months 2004'. It provides key figures for Revenues, Group EBIT, Net income, and Earnings per share, and concludes by raising the earnings outlook for the full year 2004. This structure—a brief, high-level summary of period results released outside of a full annual or quarterly report filing—is characteristic of an Earnings Release (ER). It is not a full Interim Report (IR) or Annual Report (10-K) because it is an announcement summarizing results, not the comprehensive report itself. The length (1841 chars) also supports this being a summary announcement. 9M 2004
2004-11-02 English
Q2 Report 2004
Interim / Quarterly Report
2004-08-13 German

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.